Complete genome characterization of SARS-CoV-2 is instrumental in the understanding of the COVID-19 pandemic. The emergence of variants of concern has placed a greater importance in monitoring changes to the SARS-CoV-2 genome through NGS. Gain a deeper understanding of underlying influences affecting vaccine and therapeutic efficacy by monitoring changes in the viral genome over time with our SARS-CoV-2 viral genome assay. We utilize the Ion Ampliseq SARS-CoV-2 Research Panel, a targeted amplicon sequencing chemistry, to provide complete genome coverage and accurate variant calling at low viral loads allowing for flexibility to a range of sample types. This panel consists of 2 primer pools providing redundant coverage minimizing any potential coverage dropout as a result of mutational changes in the viral genome. Using a comprehensive data analysis solution, we are able to deliver a complete SARS-CoV-2 viral genome sequence with accurate variant calling and informed annotation.
![]() |
Nasopharyngeal Swab
|
![]() |
Viral Load Quantitation
|
![]() |
Viral RNA Isolation
|
![]() |
Ion Genestudio S5 Sequencing
|
Covers >99% of the SARS-CoV-2 genome, all serotypes included
100% Accuracy and Sensitivity for SNVs and Indels above LoD
Speaker - Oswaldo A Lozoya, PhD, Genomics Staff Scientist - TSAIL, Q2 Solutions As part of the Machine Learning and Single Cell Genomics in Public Health session, Oswaldo presents insights,...
The Thermo Fisher Ion AmpliSeq SARS-CoV-2 Research Panel is a targeted NGS solution that facilitates sequence analysis of the SARS-CoV-2 genome. This assay’s performance and the Pangolin lineage...
Advances in the analysis of circulating-free DNA (cfDNA) obtained from the plasma fraction of peripheral whole blood are facilitating minimally invasive methods to monitor health and disease. As a...